Nkarta, Inc. Restructuring Charges
Nkarta, Inc. (NKTX) reported Restructuring Charges of $4.95 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-10
- Nkarta, Inc. restructuring charges for the quarter ending 2025-09-30 was -$26.00K.
- Nkarta, Inc. restructuring charges for the quarter ending 2025-06-30 was -$86.00K.
- Nkarta, Inc. restructuring charges for the quarter ending 2025-03-31 was $5.12M.
- Nkarta, Inc. restructuring charges for fiscal 2025 was $4.95M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.95M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | -$26.00K 10-Q · filed 2025-11-10 | -$112.00K derived: sum of 2 quarters · filed 2026-08-10 | $5.01M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$86.00K 10-Q · filed 2026-08-10 | $5.03M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $5.12M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |